Bullisch
$44.66
Szenariopreis
$59.280
+2.733 (+4.61%)Zum Schluss
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development, and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Orencia (abatacept), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Breyanzi (lisocabtagene maraleucel), Opdualag (nivolumab and relatlimab-rmbw), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), Sotyktu (deucravacitinib), Krazati (adagrasib), and Cobenfy (xanomeline and trospium chloride). Its other growth products include Augtyro, Onureg, Inrebic, Nulojix, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension).
Bristol-Myers Squibb is a good buy right now due to its current price of $59.12, which is below the analyst price target of $66 from BofA. Additionally, the company has a strong gross margin of 68.03% reported in Q2 2026, indicating solid profitability. However, the main risk is the declining revenue trend, with a slight decrease of 0.2% year-over-year reported for FY 2025.
Jefferies
$76
2026-10-12
Jefferies
2026-10-12
Kursziel
$76
William Blair
—
2026-10-12
William Blair
2026-10-12
Kursziel
—
BofA
$66
2026-10-09
BofA
2026-10-09
Kursziel
$66
Cantor Fitzgerald
$53
2026-10-08
Cantor Fitzgerald
2026-10-08
Kursziel
$53
Morgan Stanley
$41
2026-10-07
Morgan Stanley
2026-10-07
Kursziel
$41
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.

Bristol Myers Squibb's Mixed Results in Lung Disease Trials

Investment Choices: Bristol Myers Squibb vs. Eli Lilly

Bristol Myers Squibb Reports Positive ACTION-1 Trial Results

Diversification Reduces Dividend Risk

Comparative Investment Outlook for Bristol Myers Squibb and Novo Nordisk
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development, and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Orencia (abatacept), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Breyanzi (lisocabtagene maraleucel), Opdualag (nivolumab and relatlimab-rmbw), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), Sotyktu (deucravacitinib), Krazati (adagrasib), and Cobenfy (xanomeline and trospium chloride). Its other growth products include Augtyro, Onureg, Inrebic, Nulojix, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Bristol-Myers Squibb is a good buy right now due to its current price of $59.12, which is below the analyst price target of $66 from BofA. Additionally, the company has a strong gross margin of 68.03% reported in Q2 2026, indicating solid profitability. However, the main risk is the declining revenue trend, with a slight decrease of 0.2% year-over-year reported for FY 2025.
22 analysts cover BMY: 9 rate it Buy, 11 Hold and 2 Sell. The average price target is 55.86.

5 Trade Ideas for Monday: Applied Materials, Bristol-Myers, GE Aerospace, Howmet and Microsoft $AMAT $BMY $GE $HWM $MSFT
Mehr anzeigen
Innovation Is Driving a New Bull Market in Biotech. 16 Ways to Play It, From Our Roundtable Experts. Biotechnology stocks are soaring this year as medical advances and merger activity rekindle investor interest. More gains lie ahead, our healthcare panel says. A tidal wave of innovation in biotechnology is improving patient outcomes, transforming the industry's prospects, and lifting long-suffering biotech shares. Spurred by therapeutic breakthroughs and new-product launches, investors have bid up the iShares Biotechnology, or IBB, by 24% this year, while the State Street SPDR S&P Biotech ETF, or XBI, has risen 28%, more than twice the gain of the S&P 500. Large pharmaceutical companies are also paying attention. They have been striking licensing deals with smaller biotechs and scooping up whole companies in a bid to rebuild their pipelines and replace blockbuster drugs facing patent expirations. $MRNA $MRK $RVMD $BMY $SMMT
Mehr anzeigen
$PGR $SYK $BMY Many people enter the crypto space chasing quick profits, but real, consistent success is built on knowledge, discipline, and the right guidance. That’s where having a reliable mentor makes all the difference. Craig has played a key role in helping me understand the markets with more clarity and confidence. His approach to trading goes beyond signals, it’s about building structure, managing risk, and staying focused on long-term growth. With his guidance and his YouTube videos, I’ve been able to make smarter decisions, avoid emotional trading, and stay consistent even in volatile conditions. The shift in mindset alone has been a game changer.
Mehr anzeigenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.